AzTrials
AzTrials

Esophageal NeoplasmPhase 1/2NCT05176002

Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.

A Phase 1/2 study testing Camrelizumab in people with Esophageal Neoplasm and Immunotherapy, run by Fujian Medical University Union Hospital at 1 site in China.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

This is an exploratory phase II clinical study designed to evaluate the safety and efficacy of Camrelizumab in combination with standard radiotherapy as preoperative neoadjuvant therapy for patients with resectable esophageal squamous cell carcinoma. Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Esophageal Neoplasm, Immunotherapy, Radiotherapy
What is being tested?
Camrelizumab
Could I receive a placebo?
No, everyone receives an active treatment
How many people
25 participants
Where
1 siteChina
Study dates
10 Nov 2021to Nov 2026
Phase
Phase 1/2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Signed written informed consent prior to the implementation of any trial-related rocedures;
  • Male or female, ≥18 years of age or ≤75 years of age;
  • Patients with a confirmed diagnosis of esophageal squamous cell carcinoma by pathological histology of the primary site biopsy;
  • Patients who are judged to be operable and in need of neoadjuvant therapy by imaging and esophagoscopy ( cT1b-2N+/ cT3-4aN0-3M0), stage II-IVA;
  • The main body of the patient's tumor is located in the mid- and lower thoracic segment of the esophagus as judged by imaging and esophagoscopy (the central location of the tumor is horizontally below the arch of the odd vein, measured endoscopically ≥ 24 cm from the incisors);
  • There is at least one imaging measurable lesion according to the solid tumor efficacy evaluation criteria (RECIST version 1.1);
Show all 20Show fewer
  • The patient Have not received any prior antitumor therapy, including but not limited to surgery, radiotherapy, chemotherapy, immunotherapy, targeted therapy, etc.;
  • ECOG score 0-1;
  • Adequate organ function, subjects need to meet the following laboratory indices:
  • Absolute neutrophil count (ANC) ≥ 1.5x109/L in the last 14 days without granulocyte colony-stimulating factor ；
  • Platelets ≥ 100 x 109/L in the absence of blood transfusion in the last 14 days；
  • Hemoglobin >9 g/dL without blood transfusion or erythropoietin in the last 14 days;
  • Total bilirubin ≤1.5 x upper limit of normal (ULN); or total bilirubin >ULN but direct bilirubin ≤ ULN；
  • Portaline aminotransferase (AST), alanine aminotransferase (ALT) at ≤2.5×ULN;
  • blood creatinine ≤ 1.5 x ULN and creatinine clearance (calculated using the Cockcroft-Gault formula) ≥ 60 ml/min;
  • good coagulation function, defined as international normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 times ULN;
  • normal thyroid function, defined as thyroid stimulating hormone (TSH) within the normal range. If baseline TSH is outside the normal range, subjects with total T3 (or FT3) and FT4 within the normal range may also be enrolled;
  • Myocardial enzyme profile within the normal range (simple laboratory abnormalities that are not clinically significant, as determined by the investigator, are also allowed).
  • For female subjects of childbearing potential, a negative urine or serum pregnancy test should be performed within 3 days prior to the first dose of study drug (Cycle 1, Day 1). If a negative urine pregnancy test result cannot be confirmed, a blood pregnancy test will be requested. Non-reproductive females are defined as being at least 1 year post-menopausal or having undergone surgical sterilization or hysterectomy;
  • If there is a risk of conception, all subjects (male or female) are required to use contraception with an annual failure rate of less than 1% throughout the treatment period up to 120 days after the final study drug dose.

Who cannot join

  • patients with an untreated diagnosis of another malignancy within 5 years prior to the first dose (excluding radically treated basal cell carcinoma of the skin, squamous epithelial carcinoma of the skin, and/or radically resected carcinoma in situ)
  • patients at risk for tracheoesophageal fistula or aortoesophageal fistula
  • currently participating in an interventional clinical study treatment or have received another study drug or been treated with an investigational device within 4 weeks prior to the first dose
  • have received prior therapy with: an anti-PD-1, anti-PD-L1 or anti-PD-L2 drug or a drug targeting another stimulatory or co-suppressive T-cell receptor (e.g., CTLA-4, OX-40, CD137).
  • systemic systemic therapy with a proprietary Chinese medicine or immunomodulatory agent (including thymidine, interferon, interleukin, except for local use to control pleural fluid) with an antitumor indication within 2 weeks prior to the first dose.
  • active autoimmune disease requiring systemic therapy (e.g., with disease-relieving drugs, glucocorticoids, or immunosuppressive agents) that occurred within 2 years prior to the first dose. Alternative therapies (e.g., thyroxine, insulin, or physiologic glucocorticoids for adrenal or pituitary insufficiency) are not considered systemic therapy.
Show all 29Show fewer
  • is receiving systemic glucocorticoid therapy (excluding nasal spray, inhaled or other routes of topical glucocorticoids) or any other form of immunosuppressive therapy within 7 days prior to the first dose of the study.
  • Note: Physiological doses of glucocorticoids (≤10 mg/day of prednisone or equivalent) are permitted.
  • known allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation
  • known hypersensitivity to the active ingredient or excipients of the investigational drug Camrelizumab;
  • those with multiple factors affecting oral drug administration (e.g., inability to swallow, post-gastrectomy, chronic diarrhea, and intestinal obstruction)
  • have not recovered sufficiently from toxicity and/or complications from any intervention prior to initiation of therapy (i.e., ≤ grade 1 or at baseline, excluding malaise or alopecia)
  • known history of human immunodeficiency virus (HIV) infection (i.e., positive for HIV 1/2 antibody) and various viral hepatitis infections
  • live vaccination within 30 days prior to the first dose (Cycle 1, Day 1). Note: Injectable inactivated viral vaccine for seasonal influenza within 30 days prior to the first dose is permitted; however, intranasal administration of live attenuated influenza vaccine is not permitted.
  • women who are pregnant or breastfeeding.
  • Presence of any serious or uncontrollable systemic disease, such as
  • Resting ECG with significant and severely symptomatic uncontrollable abnormalities in rhythm, conduction or morphology, such as complete left bundle branch block, second degree or greater heart block, ventricular arrhythmia or atrial fibrillation.
  • Unstable angina, congestive heart failure, chronic heart failure of New York Heart Association (NYHA) classification ≥ 2.
  • myocardial infarction within 6 months prior to randomization
  • suboptimal blood pressure control (systolic blood pressure > 140 mmHg and diastolic blood pressure > 90 mmHg)
  • history of non-infectious pneumonia requiring glucocorticoid therapy within 1 year prior to first dose, or current clinically active interstitial lung disease.
  • active pulmonary tuberculosis.
  • the presence of an active or uncontrolled infection requiring systemic therapy
  • presence of clinically active diverticulitis, abdominal abscesses, gastrointestinal obstruction
  • the presence of liver disease such as cirrhosis, decompensated liver disease, acute or chronic active hepatitis
  • poorly controlled diabetes mellitus (fasting blood glucose (FBG) > 10 mmol/L)
  • urine routine suggesting urine protein ≥++ and confirmed 24-hour urine protein quantification >1.0 g
  • patients with mental disorders and unable to cooperate with treatment
  • have a medical history or evidence of disease that may interfere with the results of the trial, prevent the subject from participating in the study throughout, abnormal treatment or laboratory test values, or other conditions that the investigator considers unsuitable for enrollment The investigator considers that there are other potential risks unsuitable for participation in this study.

Trial locations and contacts

1 site in 1 country.

China1 site

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, 350001

Other trials in China

About this study

Official title: The Safety and Efficacy of Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Squamous Cell Carcinoma.

This is an exploratory phase II clinical study designed to evaluate the safety and efficacy of Camrelizumab in combination with standard radiotherapy as preoperative neoadjuvant therapy for patients with resectable esophageal squamous cell carcinoma. In the study, all eligible subjects who meet the inclusion criteria will be enrolled after providing full informed consent and signing the informed consent form. All enrolled patients will undergo radical surgery within 4-8 weeks after completion of neoadjuvant Camrelizumab combined with standard radiotherapy.

The safety evaluation indicators include the incidence of adverse events and the number and proportion of subjects who discontinue treatment due to adverse events. The primary efficacy endpoints are the major pathological response rate and the pathological complete response rate. Based on previous studies, the expected response rate is 40% in the experimental group and 20% in the control group. Using a one-sided alpha level of 0.1 and a beta of 0.2, the calculated total sample size for the single-arm design is 25 patients, with 12 enrolled in the first stage. If 2 or fewer responders are observed in the first stage, the study will be terminated early for futility. If more than 2 responders are observed, the trial will proceed to the second stage. Upon completion of the second stage, if the total number of responders exceeds 7, the treatment will be considered effective. The need for postoperative adjuvant treatment and the specific adjuvant regimen will be determined by the investigator. All subjects are required to complete the postoperative follow-up plan as specified in the study protocol.

Being tested
Camrelizumab
Keywords
Esophageal Neoplasm, Immunotherapy, radiotherapy, Surgery, Neoadjuvant therapy
Medical subject headings
Esophageal Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CamrelizumabDrug

    Neoadjuvant Camrelizumab combined with radiotherapy

Study groups in NCT05176002
Study groupRoleWhat they receive
Neoadjuvant Camrelizumab combined with radiotherapy groupExperimentalNot described
Receives: Drug: Camrelizumab

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Efficacy of Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.

    Major pathological remission rate

    Measured: 2 week after operation

  2. Safety of Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.

    Number and percentage of cases of all adverse events

    Measured: 2 week after operation

Secondary outcomes (1)

  1. Efficacy of Camrelizumab in Combination With Radiotherapy for Neoadjuvant

    Complete pathology remission rate

    Measured: 2 week after operation

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Jan 2022
  2. Study start10 Nov 2021
  3. Primary completion30 Sep 2023
  4. Study completionNov 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
25 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05176002
Sponsor's protocol ID
NIRE UNION
Status last verified
Dec 2024
First submitted
7 Nov 2021
Last updated
19 Nov 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Chen M, Huang Y, Zhang S, Chen C, Zeng T, Li H, Yang Z, Lin C, Li W, Xu B, Chen C, Zheng B. Neoadjuvant camrelizumab combined with radiotherapy as a chemotherapy-sparing approach for resectable locally advanced esophageal squamous cell carcinoma: a phase II clinical trial (ESOCORT-NIRT). BMC Med. 2026 Mar 9;24(1):244. doi: 10.1186/s12916-026-04781-4.

    PubMed 41803866

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing Camrelizumab in people with Esophageal Neoplasm and Immunotherapy, run by Fujian Medical University Union Hospital at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 20 inclusion and 29 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 19 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Efficacy of Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma. (time frame: 2 week after operation). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05176002, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Nov 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in